News

AbbVie Secures EU Approval for RINVOQ to Treat GCA Symptoms

AbbVie Secures EU Approval for RINVOQ to Treat GCA Symptoms

AbbVie Receives EU Approval for RINVOQ in GCA Treatment

AbbVie (NYSE: ABBV) has reached an important milestone with the European Commission's approval of RINVOQ® (upadacitinib) for treating Giant Cell Arteritis (GCA) in adult patients. This groundbreaking treatment is the first and only oral Janus kinase (JAK) inhibitor authorized in the EU specifically for GCA, offering hope to those grappling with this chronic condition.

Significance of the Approval

The approval of RINVOQ comes after successful results from the pivotal Phase 3 SELECT-GCA trial, which confirmed that upadacitinib meets critical treatment milestones. Remarkably, RINVOQ achieved a primary endpoint of sustained remission and essential secondary outcomes such as reduced disease flares and decreased steroid use. This accomplishment speaks volumes about RINVOQ’s potential in managing GCA symptoms effectively.

Understanding Giant Cell Arteritis (GCA)

GCA is an autoimmune condition that leads to inflammation of the arteries, often affecting elderly patients, primarily those over the age of 50. This disease can cause severe symptoms, including headaches and jaw pain, and raises concerns about possible vision loss. With RINVOQ now available, there is optimism for improved management and relief from these debilitating symptoms.

Insights from Medical Experts

Prof. Dr. Wolfgang Schmidt, a respected rheumatologist involved in the SELECT-GCA trial, indicated that GCA presents numerous challenges for patients. He highlighted that RINVOQ's efficacy demonstrated in clinical trials could significantly enhance patients' quality of life by aiding in sustained remission and lowering their steroid dependency—an important goal in the care of individuals with GCA.

Trial Results Highlighting Efficacy

The SELECT-GCA study included 428 patients and revealed impressive outcomes. Notably, 46.4% of patients taking RINVOQ alongside a 26-week steroid taper achieved sustained remission, a stark contrast to the 29.0% who received a placebo. Secondary endpoints also showcased significant benefits, including a noteworthy reduction in disease flares and lowered cumulative steroid usage.

Adverse Events and Safety Profile

Throughout the study, the safety profile of RINVOQ remained consistent with previous indications. Adverse events were similar across treatment groups, with no major cardiovascular events reported, providing encouraging data for its safety in patients.

Future Prospects of RINVOQ

RINVOQ's approval marks the eighth indication for this medication in the EU, broadening its use beyond conditions like rheumatoid arthritis and ulcerative colitis. This expansion reflects AbbVie's commitment to addressing areas of high unmet medical need, fulfilling their promise to support enhanced patient outcomes and provide effective therapeutic options.

Preparations for Patients and Healthcare Providers

With this recent approval, healthcare providers are now equipped with a new tool to manage GCA effectively. AbbVie is dedicated to ensuring that both patients and physicians are informed about the benefits and potential risks associated with RINVOQ. Ongoing education about GCA and strategies for its management will be crucial for optimal patient care moving forward.

Frequently Asked Questions

What is RINVOQ used for?

RINVOQ is an oral JAK inhibitor approved for treating Giant Cell Arteritis (GCA) in adult patients, among other autoimmune conditions.

Who can benefit from RINVOQ?

Adult patients with Giant Cell Arteritis, particularly those suffering from significant symptoms, may benefit from RINVOQ as a treatment option.

How effective is RINVOQ based on clinical trials?

The SELECT-GCA trial demonstrated that RINVOQ significantly increases the rate of sustained remission compared to placebo in GCA patients.

What should patients know about potential side effects?

While RINVOQ has shown to be effective, patients should discuss potential side effects with their healthcare provider to understand the benefits and risks involved.

How does RINVOQ support less steroid use?

RINVOQ has been shown in trials to reduce the need for steroid use, making it a valuable option for managing GCA without reliance on steroids.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 39

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 97

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 97

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 183

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 196

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 64

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
ASUS Brings AI Infrastructure Choices to SC26 Floor

Updated Category News Views 247

Compute buyers are sick of being handed one locked box That is the nerve ASUS is pressing at SC26: enterprises want AI infrastructure that fits the job in front of them, not somebody else's tidy product roadmap. The company is pitching a full-stack “AI Factory” blueprint built across Intel, AMD and NVIDIA hardware, running from rack-scale systems and conventional...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 119

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 93

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Freshpet's P/E Ratio: A Comprehensive Overview

Updated Category News Views 197

Understanding the Current P/E Ratio of Freshpet As we analyze the current trading performance of Freshpet Inc. (NASDAQ: FRPT), the shares are currently priced at $54.50, marking an increase of 0.70% in today’s session. Over the past month, there has been a slight rise of 0.88%. However, a significant decline of 58.54% has been noted over the last year. For shareholders,...

Continue Reading
Hilb Group Expands Footprint with New Property Acquisition

Updated Category News Views 108

Hilb Group Expands Footprint with New Property Acquisition The Hilb Group has announced an exciting addition to its portfolio through the acquisition of a property and casualty business based in Alabama. This strategic move reinforces the company's commitment to enhancing its presence in the property and casualty insurance sector. Strategic Growth Through Acquisitions In...

Continue Reading
Insurance Bad Faith: Navigating California's Rigorous Laws

Updated Category News Views 7

Understanding What Constitutes Bad Faith Insurance What does it really mean when an insurer acts in "bad faith"? Well, the legal standard doesn't leave much wiggle room in California. These aren't just bad outcomes; we're talking about conduct that defies what's reasonable under state law. Demián I. Oksenendler, a seasoned bad faith attorney, shed some light on this in a...

Continue Reading
Macrovey's Triumphant Journey at the Supply Chain Awards

Updated Category News Views 83

Macrovey's Nomination for Prestigious Supply Chain Awards Macrovey, a frontrunner in supply chain technology, is excited to share that it has been nominated for three esteemed awards at this year's Supply Chain Excellence Awards. This honor reflects the company’s ongoing dedication to improving efficiency and driving innovation in the supply chain field. Recognized...

Continue Reading
ITT Achieves Moody's Ratings Upgrade and Financial Growth Insights

Updated Category News Views 91

Moody's Ratings Upgrade for ITT Inc. ITT Inc. recently celebrated a significant achievement as Moody’s Ratings upgraded the company's credit rating from Baa2 to Baa1. This positive development underlines the company’s solid financial performance and growth strategies. The upgrade signals confidence in ITT’s ability to maintain and enhance profitability while...

Continue Reading